ReviewCanadian liver journal2020
Hepatitis C models of care: approaches to elimination.
Review in Canadian liver journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Hepatitis C Treatment Outcomes Among Immigrants: A CANUHC Cohort Analysis.Open forum infectious diseases · 2026Article
- Trends in chronic hepatitis C visits by providers in Quebec, Canada: A population-level cohort study.Canadian liver journal · 2026Article
- Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease.Nature reviews. Gastroenterology & hepatology · 2026Review
- Integrated Care Models for Hepatitis C: Lessons From Southeast Asia and Sub-Saharan Africa.Open forum infectious diseases · 2025Article
- A Bibliometric Analysis of the HCV Drug-Resistant Majority and Minority Variants.International journal of environmental research and public health · 2025Article
- Review
- Hepatitis C virus testing in infants, a move to early screening by HCV RNA at 2 months of age.Paediatrics & child health · 2025Article
- Prescribing direct-acting antivirals for hepatitis C treatment: a scoping review of factors that influence primary care providers.BMC primary care · 2025Article
- Progress Toward Hepatitis C Virus Elimination among People Living with HIV-Hepatitis C Virus Coinfection in Canada.Canadian liver journal · 2025Article
- Article
- Hepatitis C Diagnosis and Treatment Among Indigenous People in a Canadian Context: Challenges and Community-Led Solutions.Microorganisms · 2024Review
- Barriers and facilitators to implementing a Pharmacist, Physician, and Patient Navigator-Collaborative Care Model (PPP-CCM) to treat hepatitis C among people who inject drugs.The International journal on drug policy · 2023Article
- Birth cohort hepatitis C antibody prevalence in real-world screening settings in Ontario.Canadian liver journal · 2022Article
- Annual Meeting of the Canadian Association for the Study of the Liver (CASL), the Canadian Network on Hepatitis C (CanHepC), the Canadian Association of Hepatology Nurses (CAHN), and the Canadian NASH Network 2022 Abstracts.Canadian liver journal · 2022Article
- Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada.Canadian liver journal · 2021Article
- Achieving HCV micro-elimination in rural communities.Canadian liver journal · 2021Article
- Treating hepatitis C during the COVID-19 pandemic in Alberta.Canadian liver journal · 2021Article
- The 9th Canadian Symposium on Hepatitis C Virus: Advances in HCV research and treatment towards elimination.Canadian liver journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C direct-acting antivirals (DAAs) have an efficacy of 95% or greater, with pangenotypic options. Many regions in Canada have recently abolished the need to demonstrate fibrosis before treatment with DAAs, and several combination therapies are available under public and private insurance coverage. As a result, efforts to increase treatment are largely focused on engaging specific populations and providers. With minimal side effects and decreased need for monitoring, hepatitis C screening, linkage, and treatment can largely be done in a single setting. In this article, we highlight both Canadian and international examples of the specialist's ongoing role and discuss the task shifting of hepatitis C treatment to primary care; specialized community clinics; and mental health, corrections, addictions, and opioid substitution therapy settings. Although specialists continue to support most models of care described in the literature, we highlight the potential for non-specialist care in working toward the elimination of hepatitis C in Canada.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.